IRIS
COSTANTINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.848
EU - Europa 1.777
AS - Asia 729
SA - Sud America 115
AF - Africa 39
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.534
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.840
IT - Italia 380
UA - Ucraina 296
SE - Svezia 245
CN - Cina 213
SG - Singapore 210
RU - Federazione Russa 198
IE - Irlanda 181
HK - Hong Kong 155
DE - Germania 151
BR - Brasile 103
DK - Danimarca 96
GB - Regno Unito 68
TR - Turchia 64
FR - Francia 57
FI - Finlandia 55
KR - Corea 50
AU - Australia 24
CI - Costa d'Avorio 20
BE - Belgio 11
NL - Olanda 11
AT - Austria 10
MA - Marocco 10
IN - India 8
RO - Romania 6
BD - Bangladesh 5
CO - Colombia 5
MX - Messico 5
AE - Emirati Arabi Uniti 4
IQ - Iraq 4
JP - Giappone 4
AR - Argentina 3
CH - Svizzera 3
EG - Egitto 3
ES - Italia 3
DO - Repubblica Dominicana 2
EC - Ecuador 2
IL - Israele 2
TH - Thailandia 2
VN - Vietnam 2
ZA - Sudafrica 2
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CG - Congo 1
CL - Cile 1
EU - Europa 1
GA - Gabon 1
HU - Ungheria 1
IS - Islanda 1
KG - Kirghizistan 1
LV - Lettonia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PL - Polonia 1
PS - Palestinian Territory 1
PY - Paraguay 1
RS - Serbia 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 5.534
Salva come PNG Salva come JPEG
Città #
Chandler 376
Jacksonville 317
Fairfield 247
Boardman 186
Dublin 179
Hong Kong 155
Ashburn 154
Wilmington 140
Des Moines 127
Woodbridge 112
Singapore 95
Seattle 93
Ann Arbor 85
New York 80
San Mateo 73
Houston 71
Lawrence 71
Princeton 71
Redmond 58
Rome 58
Cambridge 49
San Diego 40
Centro 38
Moscow 37
Ancona 31
Beijing 27
The Dalles 24
Marche 21
Abidjan 20
Guangzhou 18
London 16
Turin 16
Melbourne 15
Istia D'ombrone 12
Los Angeles 12
Norwalk 12
Wuhan 12
Brussels 11
Washington 11
Helsinki 10
Milan 10
Shanghai 10
Civitanova Marche 9
Florence 9
Porto 9
Chiaravalle 8
Kingscliff 8
São Paulo 8
Genoa 7
Quanzhou 7
Mcallen 6
Wuxi 6
Charlotte 5
Dongguan 5
Istanbul 5
Pune 5
Rio de Janeiro 5
Vienna 5
Auburn Hills 4
Bristol 4
Castelfiorentino 4
Easley 4
Falls Church 4
Kilburn 4
Monterrey 4
Mugnano di Napoli 4
Nanjing 4
Naples 4
Nuremberg 4
Perugia 4
Pescara 4
Weihai 4
Betim 3
Bogotá 3
Bologna 3
Casoria 3
Dalian 3
Dallas 3
Dedham 3
Dhaka 3
Falconara Marittima 3
Hounslow 3
Izmir 3
Jiaxing 3
Munich 3
Napoli 3
Shenzhen 3
Taranto 3
Torre Annunziata 3
Vallefoglia 3
Zibo 3
Zurich 3
Acton 2
Amsterdam 2
Baghdad 2
Bangkok 2
Belém 2
Boydton 2
Brasília 2
Carapicuíba 2
Totale 3.439
Salva come PNG Salva come JPEG
Nome #
A novel method to evaluate prethawing viability of cryopreserved CD34+ hematopoietic stem cells for autologous transplantation. 127
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease–associated spondyloarthritis 114
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 113
Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study 110
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 106
Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals 106
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella 106
Higly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations 105
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. 103
Abnormalities of erythropoiesis during HIV-1 disease: a longitudinal analysis. 101
In vitro comparison of different TKI activity in T-Cell populations: selective sparing of Treg by Nilotinib. 99
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 99
A new method to assess the viability of collected CD34+ cells before reinfusion: a prospective study in 50 autotransplanted patients. 96
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 94
Quantification of the HIV-1 total reservoir in the peripheral blood of naïve and treated patients by a standardised method derived from a commercial HIV-1 RNA quantification assay. 92
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. 91
Effects of cryopreservation on lymphocyte immunophenotype and function 90
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. 88
Il ruolo del Medico di Medicina Generale nella diagnosi precoce della malattia da HIV. 83
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50cp/mL. 83
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina (Durability and tolerability of long-term nevirapine-based HAART). 82
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 81
Specific changes in the post-translational regulation of nucleolin in lymphocytes from patients infected with human immunodeficiency virus 80
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. 79
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV. 78
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway 76
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. 75
Efficacy and costs of Direct Acting Antivirals (DAAS) for the treatment of HCV Iinfection amnog HCV-monoinfected and HIV/HCV co-infected patients in real-life setting 74
PROGETTO E-PROs: COSTRUZIONE DI UNA PIATTAFORMA DIGITALE PER LA GESTIONE DI STRUMENTI CENTRATI SUL PAZIENTE NELLA PRATICA CLINICA (The E-PROs Project: creation of a digital platform to manage patient-oriented tools in clinical practice). 74
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 72
Genotypic Resistance Tests for the Management of Structured Therapeutic Interruptions after Multiple Drug Failure: Prosecution 71
CROI 2013: le ricadute per la pratica clinica. 71
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio 70
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 70
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study. 70
Comparsa di polmonite in soggetto con storia recente di inappetenza, disfagia, calo ponderale, ed eritema diffuso. 69
HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy 68
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 68
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 67
Diagnosi sierologica nelle malattie autoimmuni non organo-specifiche. 66
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. 66
Direct acting antivirals (DAAs) for the treatment of HCV infection in HIV/HCV coinfected patients: a clinical experience. 66
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. 66
Lo studio fenotipico di linfociti e altre cellule mononucleate. 65
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 65
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. 65
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 65
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 64
Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replicatio 63
Do we still need CD4 T cell count? 63
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 63
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients 62
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report 62
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. 61
Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale. 59
Il paziente adulto con immunodeficienza. 58
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. 58
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 56
Soluble CD163 in CMV Infected and Uninfected subjects on Virologically-Suppressive Antiretroviral therapy in the ICONA cohort 56
LA SIEROLOGIA TIPO-SPECIFICA PER HERPES SYMPLEX TIPO 2 NELLA GESTIONE DEI PAZIENTI HIV POSITIVI 55
Diagnostica immunologica. 55
Polyclonal serum-free light chains elevation in HIV-infected patients. 54
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. 54
La ricerca degli anticorpi anti-nucleo non è sempre di facile interpretazione 51
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 49
L’immunoricostituzione, un paesaggio dai mutevoli confini 48
Humoral and cellular immunity after mRNA COVID-19 vaccine in psoriatic patients on biological or immunosuppressive therapy: a real-life experience 47
Il ruolo del Mmg nella diagnosi precoce della malattia da HIV. 47
Characterisation and outcomes of difficult-to-treat patients in an Italian cohort of PLWHIV starting modern ART regimens. 46
Tollerabilità metabolica e durevolezza degli schemi antiretrovirali comprendenti nevirapina. 45
Specific Anti-Nuclear Antibodies, Clinical Features and Outcome Following Treatment with Nilotinib In Patients with Chronic Graft-Versus-Host Disease. The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Sessions 45
Infezione da HIV-1. 44
HIV among adolescents and young adults in Italy: focus on epidemiological, viro-immunological and treatment characteristics of 689 18-24 year old subjects enrolled in the ICONA Cohort. 44
Switch a raltegravir in un paziente con carcinoma a cellule di Merkel e sarcoma di Kaposi. 43
La tollerabilità della terapia antiretrovirale come mezzo per la gestione a lungo termine di pazienti complessi: un caso clinico. 42
Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT 38
La riduzione delle interazioni farmacologiche come mezzo per aumentare l’aderenza alla terapia antiretrovirale e garantirne la durability. 34
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 29
PRIMARY BILIARY CHOLANGITIS CASE- FINDING: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY ON PATIENTS WITH INCIDENTAL FINDING OF ANTI- MITOCHONDRIAL ANTIBODIES. 27
OC-34 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL 26
OC-43 ‘U=U impossibile sbagliare’ awareness campaign: impact assessment among PLWH 23
Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration 22
Activated switched memory B cell clusters in chronic spontaneous urticaria are increased in subjects with long disease duration and relapse upon omalizumab discontinuation: Results of the IL-10-OMZ study 20
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view 18
Management of vaccinations in patients with non‐Hodgkin lymphoma 17
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort 17
Totale 5.690
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020104 0 0 0 0 0 0 0 0 0 0 14 90
2020/20211.058 71 105 129 13 123 44 95 63 126 93 122 74
2021/2022585 37 129 12 34 8 31 30 52 43 48 58 103
2022/20231.153 107 121 75 118 79 230 0 61 277 4 50 31
2023/2024656 105 11 31 85 133 125 18 17 12 13 15 91
2024/20251.202 198 107 56 17 22 60 104 53 418 149 18 0
Totale 5.690